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What is already known on this subject? 
OIder people undergoing surgery often experience post-operative cognitive dysfunction (POCD), but little is 
known about pre-surgical risk factors that predispose patients to the condition. Dyslipidaemia and lipid-
lowering treatment have been implicated as risk modifiers for age-related cognitive impairment so are 
plausible potential determinants of POCD risk. 
What this study adds? 
To our knowledge, this is the first study to integrate the evidence on dyslipidaemia, lipid-lowering treatment 
and POCD risk. Our results suggest that although hypercholesterolaemia per se does not appear to be 
associated with POCD risk, statin users are at reduced risk of POCD.  
 
Abstract 
Background: Lipid imbalance is linked to age-related cognitive impairment, but its role in post-operative 
cognitive dysfunction (POCD) is unknown. Here, we present a systematic review and meta-analysis on 
dyslipidaemia, lipid-lowering treatment and POCD risk.  
Methods: PubMed, Ovid SP and Cochrane databases were searched for longitudinal studies that reported on 
associations of any measure of dyslipidaemia and/or lipid-lowering treatment with POCD as relative risks (RR) 
or odds ratios. Fixed-effects inverse variance models were used to combine effects. 
Results: Of 205 articles identified in the search, 17 studies on 2725 patients (grand mean age 67 years; mean 
age range 61 to 71 years) with follow-up periods of 1 day to 4 years (median 7 days; interquartile range 1 to 68 
days) were included. Studies focused almost exclusively on hypercholesterolaemia as a measure of 
dyslipidaemia and on statins as lipid-lowering treatment. Across 12 studies on hypercholesterolaemia, we 
found no association with POCD risk (RR=0.93; 95% CI=0.80, 1.08; P=0.34). Statin use before surgery was 
associated with a reduced POCD risk across 8 studies (RR=0.81; 95% CI= 0.67, 0.98; P=0.03), but data on 
treatment duration were lacked.  
Conclusion: Statin users appear to be at reduced risk of POCD although hypercholesterolaemia per se may not 
be associated with POCD risk. Trial studies are needed to evaluate the usefulness of statins in POCD prevention.  
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INTRODUCTION 
Surgery in older age is often accompanied by complications such as post-operative cognitive dysfunction 
(POCD) 1. POCD is not currently recognized as a condition in the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-V) and thus lacks diagnostic criteria. Nonetheless, when defined as a perioperative decline in 
function measured by a reduction in cognitive test performance, POCD is known to affect a considerable 
proportion of older adults. POCD has been reported in between 10 to 38% of older patients during the first few 
months after surgery 2 and though symptoms may resolve over time 1, it appears to persist over the course of 
years in some patients3 and irrespectively of surgery type4-6.  
Little is known about risk factors for POCD, but – given it is a type of cognitive impairment – we can turn to age-
related cognitive impairment to identify potential predictors. Increasing attention is being paid to lipid 
imbalance in this context. Markers of dyslipidaemia, such as high total cholesterol, high low-density lipoprotein 
(LDL) cholesterol, high triglycerides, and low high-density lipoprotein (HDL) have frequently been associated 
with presence 7-9 and, when measured in midlife, risk of future cognitive impairment 10,11. Pharmaceutical 
treatment for dyslipidaemia is effective, widely available and relatively cheap, and statins, the most commonly 
prescribed form of lipid-lowering treatment, have repeatedly been linked to a reduced risk of cognitive 
impairment in epidemiological studies (e.g.,  for a review, see 12).  
Potential associations of dyslipidaemia and lipid-lowering treatment with POCD risk are currently unknown, but 
warrant clarification given the high global prevalence of dyslipidaemia 13, high proportion of the population of 
developed nations on lipid-lowering treatment 14 and the large number of surgical procedures performed each 
year 15. We therefore aimed to determine whether parameters of dyslipidaemia and lipid-lowering treatment 
before surgery predict POCD risk, hypothesizing an increased and decreased risk associated with dyslipidaemia 
and lipid-lowering treatment, respectively. The totality of relevant published research was combined for overall 
estimates. 
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METHODS 
Systematic search strategy 
A search was performed on 13th June 2017 of the PubMed, Ovid SP and Cochrane Database of Systematic 
Reviews, combining terms on parameters of dyslipidaemia (total cholesterol, LDL, HDL, triglycerides, and 
related terms) and those on lipid-lowering treatment with terms on cognitive dysfunction after surgery: 
(((cholesterol[tiab] OR low-density lipoprotein[tiab] OR high-density lipoprotein[tiab] OR LDL[tiab] OR 
*HDL[tiab] OR triglycer*[tiab] OR TC[tiab] OR dyslipid*[tiab] OR hypercholest*[tiab] OR lipid-lowering[tiab] OR 
statins[tiab] OR *statin[tiab] OR ezetimibe[tiab] OR ezetrol[tiab]))) AND ((post-operative cognit*[tiab] OR 
postoperative cognit*[tiab] OR POCD[tiab]) OR (("surgery"[tiab] OR "operation"[tiab]) AND ("cognit"[tiab] OR 
"intelligence"[tiab] OR "MMSE"[tiab] OR "Mini Mental"[tiab] OR "dementia"[tiab] OR "Alzheim*"[tiab] OR 
"mild cognitive impairment"[tiab] OR "MCI"[tiab]))). Following exclusion of duplicates, abstracts of all ‘hits’ 
were screened for potential matching to inclusion criteria (see Figure 1). Reference lists of relevant review 
articles and of included studies were hand searched for further relevant articles, and an online search was 
performed. Our approach complies with guidelines issued by the Meta-analysis Of Observational Studies in 
Epidemiology (MOOSE) and Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) 16,17. The search was registered on the PROSPERO database (CRD42017069013).  
 
Study selection 
Studies were included if all of the following criteria were met: i) longitudinal study design, ii) sample of human 
adults (≥18 years old) undergoing surgery, iii) full text in English language, iv) exposure to any parameter 
indicative of dyslipidaemia, or exposure to lipid-lowering treatment, ascertained before surgery, v) reporting of 
exposure associations with risk of POCD as relative risks (RR) or odds ratios (both taken as RR for the purpose 
of the present analysis or in a form that allowed calculation of RR). Studies with observational design and 
intervention studies were considered separately. Studies on lipid-lowering treatment at hospital discharge 
were excluded. Prescription of lipid-lowering drugs at discharge is affected by economic and health-related 
factors, and does not necessarily correlate with long-term pre-operative treatment 18.  
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Data extraction 
Data were extracted and tabulated for country of origin, type of anesthesia and surgery, patient number, 
proportion of males, follow-up period, definition of POCD, associations of exposure to measures of 
dyslipidaemia or lipid-lowering treatment with POCD (RR), and covariates. For each study, the respective 
longest follow-up period and fully adjusted models (if any adjustment was applied) were considered. Duplicate 
reporting was identified by comparison of authors, institutions and sample characteristics between articles. 
Where duplicate reporting was suspected, the article with the most complete reporting was selected for 
inclusion. Corresponding authors were contacted for unreported statistical detail. This way, unpublished data 
was obtained for one study 19.  
 
If unspecified, the term “cholesterol” was taken to mean “total cholesterol”, and “statins” were seen to refer to 
pre-operative statin use. Three articles had insufficient reporting of data on exposure associations with POCD 
for their respective longest follow-up periods, so data on shorter follow-ups were used 20-22. In 2 studies, POCD 
was graded according to severity, and the category reflecting the most severe dysfunction was selected for 
analysis 22,23.  
 
Data synthesis 
Data were entered into Review Manager 5.3 (Cochrane Collaboration, 2014). For each exposure, inverse 
variance meta-analyses pooled risk estimates across included studies to obtain summary estimates (95% 
confidence intervals, CI). Fixed-effects models were selected based on the assumption that effect sizes  
reported for each study estimate one true underlying population effect size 24. Analyses were repeated post-
hoc with random-effects models which are more conservative compared with fixed-effects models. Funnel 
plots assessed publication bias and pre-specified meta-regression analyses compared risk estimates between 
groups of studies according to follow‐up period (≤1 versus >1 month), sample size (≤100 versus >100), mean 
sample age (≤65 versus >65 years), surgery type (cardiac; non-cardiac; and mixed surgery type) and sex (≤75% 
males versus >75% males). Cut-points for all of those subgroups analyses were specified a priori; one additional 
subgroup analysis comparing risk estimates according to definition of “hypercholesterolaemia” was performed 
post-hoc. Meta-regression was calculated in SAS Enterprise Guide (version 4.3).  
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Quality assessment 
Reporting quality was assessed by one investigator (IF) using the 22-item checklist for cohort studies issued by 
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Initiative 
 25. A score of reporting quality was derived based on the number of items an article scored positively on 
(maximum score 22). Of note, the STROBE checklist is limited to reporting quality and does not reflect the 
quality of a study.  
 
RESULTS 
Study characteristics 
A total of 171 unique articles identified in the search and 34 articles were identified independently (see Figure 
1). Of all articles, 17 met inclusion criteria. All included studies had observational designs. 
 
Publication years spanned 2001 to 2017 and studies stemmed from USA, Asia, Europe and Australia. One US 
lab was overrepresented but appeared to report on different patient samples in each of their articles 26-30 (see 
Supplemental Table 1). Studies included a total of N=2725 patients who were followed up for between 1 day 
and 4 years after surgery (median 7 days; interquartile range 1 to 68 days). Where reported, mean sample age 
ranged from 61 to 71 years (mean 67 years). All except one study 19 had recruited more males than females. 
Surgical procedures included cardiac surgery (N=8) and non-cardiac surgery (N=8); one study included both 21.   
 
POCD was defined inconsistently. Two studies identified POCD using brief screening instruments31,32 and 1 
study defined it through consensus rating by two neuropsychologists 23 (see Supplemental Table 1). All of the 
remaining investigations used detailed batteries of cognitive testing. Of these, 5 used raw change in cognitive 
scores to define POCD18,20,33-35 and 9 compared patients’ cognitive change to control subjects who performed 
the same battery of cognitive tests but did not undergo surgery 19,21,22,26-30,36.  
Of all included studies, only 2 had set out to address the present research question 18,27. All of the remaining 
investigations reported on parameters of dyslipidaemia or lipid-lowering treatment and POCD risk in 
descriptive form. Statistical adjustment for potential confounders was rare. 
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Parameters of dyslipidaemia 
A single study assessed total cholesterol, LDL, HDL and triglycerides as continuous measures of dyslipidemia 26; 
another reported on hypertriglyceridemia but did not specify cut-offs 23. Twelve articles reported on 
hypercholesterolaemia. Of these, 1 used a combination of self-report and medical history for definition 19, 4 
used laboratory measurements (total cholesterol ≥240 mg/dl 23; total cholesterol ≥240 mg/dl and/or 
triglycerides ≥150 mg/dl 33; total cholesterol ≥200 mg/dl and/or medication 29,30), and 7 used the terms 
“hypercholesterolaemia” or “hyperlipidemia” without definition 20,21,31,32,34-36. Eight articles reported on statin 
use 18,22,26-30. Of those 8 articles, only 2 specified that statins were taken pre-operatively 18,21. For the remaining 
6 studies, we inferred this based on the fact that data were presented in tables showing baseline 
characteristics of patient samples 22,26-30. No studies on forms of lipid-lowering treatment other than statins 
were found.  
 
Findings of included studies 
Total cholesterol, LDL, HDL, triglycerides 
In the study on continuous parameters of dyslipidaemia, total cholesterol (RR=1.00; 95% CI 0.99, 1.01; p=0.72), 
LDL (RR=1.00; 95% CI=0.99, 1.01; p=0.79), HDL (RR=1.03; 95% CI=1.00, 1.07; p=0.59) and triglycerides (RR=1.00; 
95% CI=0.99, 1.01; p=0.78) were each unrelated to POCD risk at 1 day after surgery 26. 
 
Hypertriglyceridemia 
“Hypertriglyceridemia” was unrelated to POCD risk at 6-month follow-up (RR=2.21, 95% CI=0.34, 4.30; p=0.77) 
in the only study to assess this risk factor 23.  
 
Hypercholesterolaemia: Meta-analysis 
Twelve studies were entered into meta-analysis on hypercholesterolemia. When results were pooled across all 
of those studies, we found no association of hypercholesterolemia exposure with risk of POCD (RR=0.93; 95% 
CI=0.80, 1.08; p=0.34) (see Figure 2). There was no evidence of statistical heterogeneity (chi2 (11)=10.65; 
p=0.47; I2=0%) or publication bias (see Supplemental Figure 1). A random-effects model yielded identical 
results (RR=0.93; 95% CI=0.80, 1.08; p=0.34).  
 
8 
 
Hypercholesterolaemia: Subgroup analysis and meta-regression 
Hypercholesterolaemia did not predict POCD risk in any of the subgroup analyses according to follow-up 
period, sample size, age, surgery type, proportion of males, or definition of “hypercholesterolaemia” (all 
p>0.10; Supplemental Table 2). Effect sizes also did not differ statistically significantly between subgroups (all 
meta-regression p>0.10).  
 
Statin use: Meta-analysis 
Across 8 included studies with data on pre-operative statin use and POCD risk, exposure to statins was 
associated with a reduced risk of POCD (RR=0.81; 95% CI=0.67, 0.98; p=0.03) with evidence of moderate 
statistical heterogeneity between studies (chi2 (7) = 11.96; p=0.10; I2=41%; see Figure 3). Only 2 of the 8 studies 
considered sociodemographic, genetic and clinical covariates in their analyses 21,26. Those 2 studies did not 
weigh heavily in the meta-analysis due to large standard errors of their estimates (see Figure 3), so that the 
pooled risk estimate can be considered largely unadjusted. Results were similar but were no longer statistically 
significant when a random-effects model was used (RR=0.76; 95% CI=0.57, 1.01; p=0.059) and there was no 
evidence of publication bias (see Supplemental Figure 2).  
 
Statin use: Subgroup analysis and meta-regression  
Results from subgroup analyses are shown in Figure 4 and Supplemental Table 3. The association of pre-
operative statin use with POCD risk did not differ statistically significantly between groups of studies according 
to follow-up period (≤1 month, RR=0.71, 95% CI=0.55, 0.92; >1 month RR=0.93, 95% CI=0.71, 1.22; meta-
regression p=0.257), sample size (≤100, RR=0.49, 95% CI=0.31, 0.78; >100, RR=0.89, 95% CI=0.73, 1.09; meta-
regression p=0.538), mean sample age (≤65 years, RR=0.93, 95% CI=0.71, 1.22; >65 years, RR=0.77, 95% 
CI=0.55, 1.07; meta-regression P=0.442) or sex (≤75% males, RR=0.84, 95% CI=0.69, 1.02; >75% male, RR=0.60, 
95% CI=0.32, 1.13; meta-regression p=0.364). However, when results were pooled according to surgery type, 
the association of statin use with POCD risk only reached statistical significance in studies of non-cardiac 
surgery (RR 0.60, 95% CI 0.44, 0.80). That risk estimate was lower than that of a study with mixed surgery type 
which had applied statistical adjustment for sociodemographic and clinical covariates including 
hypercholesterolaemia and failed to find statistically significant associations of statin use with POCD risk  
(RR=1.37, 95% CI=0.78, 2.39; meta-regression p=0.049). A trend was observed for a lower risk estimate in the 
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subgroup of studies on non-cardiac surgery compared with a study of patients undergoing cardiac surgery 
(RR=0.93, 95% CI=0.71, 1.22; meta-regression p=0.079).  
 
Statin use: Narrative evidence on statin type, dosage, and use at hospital discharge 
Of the 8 included studies on statin use, one assessed statin type and dosage. The study reported that statin 
non-users were at similar POCD risk compared with a group receiving atorvastatin (RR=1.26, 95% CI=0.71, 2.26; 
p=0.421) whereas non-users were at increased risk compared with a group on simvastatin (RR=6.65; 95% 
CI=1.63, 27.22; p=0.008). Relative to the latter group, patients receiving atorvastatin, too, were at increased 
risk (RR=5.27; 95% CI=1.25, 22.26; p=0.024). Interestingly, the study also suggested that there may be a dose-
response relationship of statins with POCD risk. Patients treated with maximum dosage of any statin were at 
reduced risk compared with patients receiving sub-maximum dosage (RR=0.17, 95% CI=0.04, 0.71; p=0.001) 
although results of that study were limited by large confidence intervals 27. One study additionally assessed 
statins at discharge (rather than pre-operatively) and found that of 100 patients discharged on statins (of 
whom 21 received statins for the first time), 42.0% had POCD at 6 week follow-up compared with 34.5% not 
receiving statins (RR=1.23, 95% CI=0.93, 1.60; p=0.173). Yet, when cognitive change was modeled as a 
continuous outcome, statins at discharge were statistically significantly associated with a reduced rate of 
cognitive improvement (p=0.011) 18. 
 
Excluded studies 
A number of studies failed to meet inclusion criteria but are considered here as additional evidence. Those on 
parameters of dyslipidaemia all reported no association with POCD risk.  In one study of 124 patients with 
diabetes, “hypercholesterolaemia” was entered but not retained in models of 7-day and 6-month POCD risks 
but the article did not report effect sizes 37. Another study that followed 54 coronary artery bypass graft (CABG) 
patients for 3 to 5 years described that there was no association of “hyperlipidemia” before surgery with POCD 
risk. Statistical results were not provided 38. In a sample of 55 older adults undergoing non-cardiac surgery, 
“hypercholesterolaemia” before surgery was not associated with cognitive decline to 1 month follow-up 
(p=0.61) 39. One study of 40 patients undergoing intracranial surgery reported no association of Mini-Mental 
State Examination (MMSE) scores with “dyslipidaemia” (p=0.97) but did not specify whether the analysis was of 
pre-surgery, post-surgery or change in MMSE scores 40. Finally, in one of the earliest studies of POCD, higher 
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cholesterol levels correlated with higher motor speed at 1 month after cardiac surgery (p=0.015), but the 
article did not report on effect sizes, and we have concerns over whether “motor speed” was interpreted in the 
correct direction. Cholesterol did not correlate with any of the other 7 cognitive tests in that study 41.  
 
One observational study on lipid-lowering treatment failed to meet our inclusion criteria due to assessing statin 
use at hospital discharge only. In that study of 229 cardiac surgery patients, 126 (55.0%) had developed POCD 
by 1-year follow-up and statin use at discharge was unrelated to POCD risk (RR=1.10, 95% CI=0.87, 1.38; 
p=0.441) 42. Two trials were excluded from our analysis due to non-English language 43 or initiation of statin 
treatment after surgery 44. One Russian study compared the effects of pre-operative rosuvastatin treatment for 
10 to 14 days before surgery and until hospital discharge versus not receiving that treatment. The sample 
consisted of 109 middle-aged to older males undergoing CABG, and at 7 to 10-day follow-up the group 
receiving rosuvastatin outperformed the control group on tests of memory, attention and processing speed 43. 
The finding is contrasted with a recent UK randomized controlled trial. Here, either simvastatin or placebo was 
administered to 142 patients and no effect of intervention on risk of POCD 6 months after surgery was found 44. 
However, that study was of critically ill patients, i.e. not necessarily representative of the general older 
population undergoing surgery, had high loss to cognitive follow-up (66.2%) and, unlike the Russian trial 43 
initiated statin treatment immediately after surgery 44. Effects of longer-term pre-operative statin use on POCD 
risk were not addressed. 
 
DISCUSSION 
In this systematic review, we had set out to combine the evidence on parameters of dyslipidaemia and lipid-
lowering treatment as potential modifiers of POCD risk. Across 17 included studies, the exposure under 
assessment was limited almost exclusively to hypercholesterolaemia and statin use, and studies reported 
predominantly unadjusted, descriptive data. Hypercholesterolaemia – though defined inconsistently across 
studies – was overall not associated with POCD risk, whereas use of pre-operative statins was linked to a 
19%reduction in POCD risk. The association of statins with a reduced risk appeared to be limited to studies of 
non-cardiac surgery type although the study number in the subgroup analysis according to surgery type was 
insufficient to allow definitive conclusions. There was further preliminary epidemiological evidence (albeit 
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based on a single article) suggestive of an inverse dose-response relationship of statins and POCD risk as well as 
superiority of simvastatin over atorvastatin in POCD prevention 27.  
 
Cholesterol is known to have atherogenic 45, pro-inflammatory 10 and beta amyloid promoting properties 12. 
Dyslipidaemia also appears to cause POCD in animal studies 46. Further, dyslipidaemia is a relatively well-
established risk factor for age-related cognitive impairment  7. On that basis, we had expected to find a link to 
POCD, and can only speculate as to underlying reasons. Firstly, the epidemiological evidence on age-related 
cognitive impairment suggests a role of midlife dyslipidaemia 47,48 more so than of cholesterol measured in 
later life 49-52 (for reviews, see 10,11). For instance, in the Women’s Health and Aging Study II, total and HDL 
cholesterol measured at age 75 did not predict cognitive decline during 9-year follow-up 53. The disparity of 
midlife versus late-life cholesterol levels may in part be due to an effect of cognitive impairment on reducing 
cholesterol levels  54. In the studies included in our analysis, hypercholesterolaemia was ascertained 
immediately before surgery, i.e. in later life. Secondly, “hypercholesterolaemia” was frequently undefined in 
the included studies, and in those studies may well have been based on a combination of laboratory 
measurements with statin use. In that case, detrimental effects of cholesterol itself on POCD risk were perhaps 
eliminated by statin users in the “hypercholesterolemia” groups. Finally, it is possible that dyslipidemia is in fact 
unrelated to POCD risk. Analyses of genetic biomarkers appear to support this explanation. The e4 allele of 
apolipoprotein E (ApoE) gene involved in cholesterol metabolism is a well-established risk factor for cognitive 
impairment 55, but reports on associations with POCD have been mixed 19,28,56. 
 
A number of epidemiological studies have implicated statin use as reducing the risk of future age-related 
cognitive impairment 12. For instance, women participating in the Heart and Estrogen/Progestin Replacement 
Study who received statins had higher cognitive function compared with non-users 8. Reduced risk of POCD in 
statin users is also in line with beneficial effects on other post-operative outcomes such as risk of stroke and 
cardiovascular events 57,58. Importantly, we had no information on duration of statin treatment for any of the 
included studies; patients’ statin use over the course of decades prior to surgery is thus unknown. Given that 
the trial that had initiated statins after surgery found no effect on POCD risk 44 whereas the Russian study that 
had used statins for 10 to 14 days before surgery reported beneficial effects 43 implies a central role of 
treatment duration in risk modification which warrants clarification in future randomized controlled trials.  
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With statins as a form of lipid-lowering treatment, it would appear plausible that any associations of statins 
with reduced POCD risk are due to reduced cholesterol levels in statin users, but two arguments speak against 
this. Firstly, we did not find an association of hypercholesterolaemia itself with POCD risk. Secondly, the study 
that had compared statin types found that patients receiving simvastatin were at lower risk of POCD compared 
with those on atorvastatin 27 despite the latter as the more intensive form of lipid-lowering drug59.   
 Alternative underlying causal mechanisms linking statins to a reduced risk of POCD may include anti-
thrombotic and anti-inflammatory effects, as well as effects on endothelial function 60. Statins further reduce 
beta amyloid levels – a hallmark of Alzheimer’s disease – and have been linked to a lower severity of 
Alzheimer’s disease pathology in observational studies 12. Contrasting with the epidemiological evidence 
presented here and with the Russian trial showing a beneficial effect of statins on POCD risk 43, trials on age-
related cognitive impairment have been unpromising, however. Some RCTs have suggested that statins may 
temporarily lead to cognitive decrements 61 – a concern that even led to the US Food and Drug Administration 
to include cognitive side-effects in its safety profile of statins 62; whereas others including a Cochrane review of 
RCTS reported no effect of statins on cognitive decline 63,64 . Similarly, for PCSK9 inhibitors as another form of 
lipid-lowering drug, a meta-analysis reported adverse cognitive effects. However, that analysis was affected by 
low study number and inconsistent definition of cognitive outcome that included confusional states65. A more 
recent RCT reported no effects of PCSK9 inhibition on 19-month cognitive decline 66 so that overall the 
evidence from RCTs on the roles of statins and PCSK9 inhibitors in age-related cognitive decline is not entirely 
clear at present.  
 
In light of potential adverse effects of lipid-lowering treatment on cognitive function, tThe present 
epidemiological evidence of a reduced risk of POCD in statin users may well be due to counterbalancing of 
statin-induced cognitive decrements by reduced cholesterol levels. The finding could also reflect reverse 
causality. Statin use may depend on a range of factors such as cognitive reserve indexed by socioeconomic 
status, education and pre-morbid intelligence. People with a lower cognitive reserve may have lower 
healthcare uptake 67 and also appear to be at reduced risk of POCD 68. Relatedly, people with beginning 
cognitive impairment in older age may have difficulty with treatment adherence 69 and are also at increased 
POCD risk 1. Confounding by other factors such as health status at the time of undergoing surgery, too, is 
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possible. The association of statins with reduced POCD risk could therefore be spurious. We are unable to 
determine this from the present data.  
 
The unclear role of causality in statin use and POCD risk limits the clinical implications of our findings. Trials 
mirroring the recent Russian investigation 43 with additional inclusion of a placebo group are needed and 
should test for dose-response and statin-type-specific effects. Comparison of benefits according to duration of 
treatment before surgery is also necessary to determine whether patients benefit from short-term treatment 
initiated at the time when surgery is planned.  
 
Strengths of our study include the systematic search of three databases with wide inclusion criteria that 
captured studies which did not label their outcome “POCD”.  Our analysis is limited by heterogeneous sample 
characteristics and length of follow-up between included studies. Heterogeneity in cut-offs of laboratory data 
and parameters used for definition of “hypercholesterolaemia” highlights the need for streamlining of research 
studies. Finally, no data on duration of treatment were reported in any of the included studies on statins so 
that we are unable to comment on risk modification associated with long-term versus short-term use. 
 
In the first systematic review of parameters of dyslipidaemia and lipid-lowering treatment before surgery as 
potential modifiers of POCD risk, we found evidence of a reduced risk of POCD in statin users. We are unable to 
determine the role of treatment duration on the basis of the present data. Questionable causality in the 
association of statin use with age-related cognitive decline further suggests confounding of the association, so 
that further trial studies manipulating duration of treatment, as well as statin type and dosage are urgently 
needed. 
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